You are here

Articles

Biomarker Predicts Worse Outcome in Chronic Myeloid Leukemia

published: 5 February 2012

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

published: 30 January 2012

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors: David Marin et al

published: 25 January 2012

Chronic Myeloid Leukemia 2010:Where Are We Now and Where Can We Go? Jerald P. Radich

published: 24 January 2012

Poor response to second-line kinase inhibitors in CML patients with multiple low-level mutations, irrespective of their resistance profile

published: 22 January 2012

CML Support Group: Response to the Appeal Panel Judgement

published: 16 January 2012

NICE say NO to dasatinib and high dose IM. Full Guidance

published: 15 January 2012

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure? Junia V. Melo1 and David M. Ross2

published: 13 January 2012

CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley OncologySTAT Editorial Team. Nov 23 2010

published: 10 January 2012

2-year follow-up from a randomized phase 3 trial (DASISION)

published: 10 January 2012

CMLSg's Campaigning Activity 2011

published: 6 January 2012

Possible cure for leukemia found by Penn State researchers

published: 4 January 2012

Subcutaneous Omacetaxine Effective in Chronic- or Accelerated-Phase CML Resistant to 2 or More TKIs

published: 21 December 2011

Bosutinib Active in Patients With Philadelphia Chromosome–Positive Leukemia Resistant to Second-Generation TKIs Posting Date: December 13, 2011

published: 21 December 2011

DCC-2036: 'Switch Pocket' inhibitor in phase 1 trial for resistant CML plus ALL and AML

published: 10 December 2011

STOP 2G-TKI Study

published: 7 December 2011

Biomarker Predicts Worse Outcome in CML

published: 7 December 2011

Durable complete molecular remission of CML following dasatinib cessation, despite adverse disease features

published: 25 November 2011

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

published: 21 November 2011

ASH 2010 - Orlando- by Prof. Stephen O'brien

published: 16 November 2011